Insmed (INSM) reported a first quarter net loss of $163.6 million, or $0.76 per share, compared to a net loss of $256.6 million, or $1.42 per share, a year ago. Product revenues, net, was $305.96 million compared to $92.82 million.
The company reiterated 2026 BRINSUPRI revenue guidance of at Least $1 billion and 2026 ARIKAYCE revenue guidance of $450 million to $470 million.
As of March 31, 2026, Insmed had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion.
In pre-market trading on NasdaqGS, Insmed shares are down 5.15 percent to $130.04.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.